STOCK TITAN
  1. Home
  2. News
  3. BJDX

Bluejay Diagnostics Inc - BJDX STOCK NEWS

Welcome to our dedicated news page for Bluejay Diagnostics (Ticker: BJDX), a resource for investors and traders seeking the latest updates and insights on Bluejay Diagnostics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bluejay Diagnostics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bluejay Diagnostics's position in the market.

News
Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering
Rhea-AI Summary
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) announced the closing of a public offering of 2,692,308 shares of common stock and warrants, generating approximately $3.5 million in gross proceeds. The company intends to use the net proceeds for obtaining FDA approval, clinical studies, research and development, and general working capital needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
offering
-
News
Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering
Rhea-AI Summary
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) announced the pricing of a public offering of 2,692,308 shares of common stock and warrants to purchase up to 2,692,308 shares at a combined offering price of $1.30 per share. The offering is expected to close on December 28, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.48%
Tags
offering
-
News
Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)
Rhea-AI Summary
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) announces the initiation of a multicenter clinical study to evaluate the Symphony IL-6 test in sepsis patients, positioning the company to move forward with multiple initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.5%
Tags
clinical trial
News
Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) reported its financial results for the quarter and nine months ended September 30, 2023. The company focused on implementing a modified clinical strategy based on FDA feedback and plans to submit for regulatory approval for Symphony IL-6 in the first half of 2024. Bluejay renegotiated its licensing and supply agreements with Toray Industries, Inc., reducing royalty payments and securing critical component supply for the Symphony Cartridge. Symphony IL-6 testing has the potential to improve outcomes for sepsis patients by enabling healthcare providers to better prioritize care. Cash and cash equivalents on September 30, 2023, were $5.08 million, with an estimated sufficient fund to operate into the first quarter of 2024. The company expects to seek additional capital through various means for its planned operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
earnings
-
News
Bluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Rhea-AI Summary
Bluejay Diagnostics, Inc. announces purchase and sale of 216,000 shares of common stock in a registered direct offering and concurrent private placement. Gross proceeds expected to be approximately $1.59 million. Net proceeds to be used for FDA approval, research and development, and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.63%
Tags
offering
-
News
Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Bluejay Diagnostics, Inc. announced financial results for the six months ended June 30, 2023. The company is developing the Symphony IL-6 test on its Symphony platform, which has the potential to predict clinical deterioration in sepsis patients. The company submitted a pre-submission application to the FDA and intends to proceed as planned based on the FDA's feedback. Cash and cash equivalents on June 30, 2023, were $5.1 million. Research and development expenses increased to $3.0 million, while general and administrative expenses decreased slightly to $2.3 million. Sales and marketing expenses increased to $302,000. The net loss for the six months ended June 30, 2023, was $5.4 million, or $5.24 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
earnings
News
Bluejay Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
none
-
News
Bluejay Diagnostics Announces Reverse Stock Split
Rhea-AI Summary
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) has announced a reverse stock split at a ratio of 1-for-20. The split will reduce the number of authorized outstanding shares from 100,000,000 to 7,500,000 and will be effective on July 24, 2023. The purpose of the reverse stock split is to increase the per share trading price to comply with the minimum $1.00 bid price requirement for continued listing on The Nasdaq Capital Market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.15%
Tags
none
-
News
Bluejay Diagnostics Updates Symphony IL-6 Regulatory Strategy
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
none
News
Bluejay Diagnostics Reports First Quarter 2023 Financial Results
Rhea-AI Summary
Bluejay Diagnostics announces financial results for Q1 2023, with cash and cash equivalents at $6.8 million. R&D expenses increase due to personnel costs and clinical trials. General and administrative expenses decrease. Net loss is $2.5 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
earnings
Stock BJDX logo
Bluejay Diagnostics Inc

Nasdaq:BJDX

BJDX Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

BJDX Stock Data

1.48M
1.90M
16.92%
7.42%
0.41%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Acton

About BJDX

bluejay diagnostics, inc. is a medical diagnostics company focused on improving patient outcomes using its symphony system, a cost-effective, rapid, near-patient product for triage and monitoring of disease progression.